About Johnson & Johnson
https://www.jnj.comJohnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue.
CEO
Joaquin Duato
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2001-06-13 | Forward | 2:1 |
| 1996-06-12 | Forward | 2:1 |
ETFs Holding This Stock
VTS.AX
Weight:0.76%
Shares:75.60M
IVV.AX
Weight:0.84%
Shares:30.86M
XWD.TO
Weight:0.61%
Shares:30.86M
Summary
Showing Top 3 of 1,058
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Goldman Sachs
Buy
Citigroup
Buy
Guggenheim
Buy
UBS
Buy
RBC Capital
Outperform
Raymond James
Outperform
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:236.62M
Value:$51.71B
BLACKROCK, INC.
Shares:207.26M
Value:$45.3B
BLACKROCK INC.
Shares:198.19M
Value:$43.31B
Summary
Showing Top 3 of 5,518
About Johnson & Johnson
https://www.jnj.comJohnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $23.99B ▲ | $9.59B ▲ | $5.15B ▼ | 21.47% ▼ | $2.12 ▼ | $9.29B ▲ |
| Q2-2025 | $23.74B ▲ | $9.3B ▲ | $5.54B ▼ | 23.32% ▼ | $2.29 ▼ | $8.74B ▼ |
| Q1-2025 | $21.89B ▼ | $8.24B ▼ | $11B ▲ | 50.24% ▲ | $4.57 ▲ | $15.61B ▲ |
| Q4-2024 | $22.52B ▲ | $11.55B ▲ | $3.43B ▲ | 15.24% ▲ | $1.43 ▲ | $5.92B ▲ |
| Q3-2024 | $22.47B | $10.23B | $2.69B | 11.99% | $1.12 | $5.38B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $18.56B ▼ | $192.82B ▼ | $113.54B ▼ | $79.28B ▲ |
| Q2-2025 | $18.88B ▼ | $193.39B ▼ | $114.92B ▼ | $78.47B ▲ |
| Q1-2025 | $38.78B ▲ | $193.67B ▲ | $115.56B ▲ | $78.11B ▲ |
| Q4-2024 | $24.52B ▲ | $180.1B ▲ | $108.61B ▲ | $71.49B ▲ |
| Q3-2024 | $20.3B | $178.29B | $108.13B | $70.16B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.15B ▼ | $9.17B ▲ | $-542M ▲ | $-8.93B ▼ | $-346M ▲ | $8.38B ▲ |
| Q2-2025 | $5.54B ▼ | $3.88B ▼ | $-18.26B ▼ | $-5.67B ▼ | $-19.9B ▼ | $2.48B ▼ |
| Q1-2025 | $11B ▲ | $4.17B ▼ | $-297M ▲ | $10.42B ▲ | $14.37B ▲ | $3.37B ▼ |
| Q4-2024 | $3.43B ▲ | $6.98B ▼ | $-1.32B ▲ | $-1.34B ▲ | $4.13B ▲ | $4.84B ▼ |
| Q3-2024 | $2.69B | $7.99B | $-3.13B | $-9.88B | $-4.9B | $5.71B |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Innovative Medicine | $14.33Bn ▲ | $13.87Bn ▼ | $15.20Bn ▲ | $15.56Bn ▲ |
 MedTech | $8.19Bn ▲ | $8.02Bn ▼ | $8.54Bn ▲ | $8.43Bn ▼ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 AsiaPacific Africa | $3.26Bn ▲ | $3.31Bn ▲ | $3.61Bn ▲ | $3.61Bn ▲ |
 Europe | $4.92Bn ▲ | $5.11Bn ▲ | $5.39Bn ▲ | $5.44Bn ▲ |
 UNITED STATES | $13.20Bn ▲ | $12.30Bn ▼ | $13.54Bn ▲ | $0 ▼ |
 Western Hemisphere excluding US | $1.14Bn ▲ | $1.17Bn ▲ | $1.21Bn ▲ | $1.23Bn ▲ |
CEO
Joaquin Duato
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2001-06-13 | Forward | 2:1 |
| 1996-06-12 | Forward | 2:1 |
ETFs Holding This Stock
VTS.AX
Weight:0.76%
Shares:75.60M
IVV.AX
Weight:0.84%
Shares:30.86M
XWD.TO
Weight:0.61%
Shares:30.86M
Summary
Showing Top 3 of 1,058
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Goldman Sachs
Buy
Citigroup
Buy
Guggenheim
Buy
UBS
Buy
RBC Capital
Outperform
Raymond James
Outperform
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:236.62M
Value:$51.71B
BLACKROCK, INC.
Shares:207.26M
Value:$45.3B
BLACKROCK INC.
Shares:198.19M
Value:$43.31B
Summary
Showing Top 3 of 5,518